BBIO at a glance
BridgeBio Pharma, Inc. (BBIO, SEC CIK 1743881) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), BridgeBio Pharma, Inc. (BBIO) reported revenue of $502.1 million (up 126.3% from FY2024) and a net loss of $724.9 million. Diluted EPS was -$3.78.
- As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding BridgeBio Pharma, Inc. (BBIO) shares worth $5.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Kumar Neil on November 19, 2026 of 8,500 shares at $78.35 per share.
- In the last 90 days, BBIO insiders reported 0 open-market purchases ($0) and 9 open-market sales ($5.1M) on Form 4, a net sale of $5.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $502.1M
- +126.3% vs prior year
- Insiders · 90 days
- 0 buys · 9 sells
- Net −$5.1M
- 13F holders
- 35 funds
- $5.0B · −3 vs prior quarter
- Latest 8-K
- Oct 29, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Biopharmaceutical development and commercialization with focus on genetic diseases and novel therapies
- New emphasis on commercialization with FDA approval and US launch of Attruby (net product revenue $362.4M in 2025)
- Strategic shift: Exclusive EU license of acoramidis to Bayer and sale of royalty rights generating $300M upfront cash
- Increased SG&A expenses by $242.3M in 2025 supporting commercial launch of Attruby; R&D expenses decreased $54.5M due to program reprioritization
- Raised $619.3M net from 0.75% convertible notes due 2033 in 2026, used partly for common stock repurchase and refinancing debt
Risk Factors
- Cybersecurity risk managed by multidisciplinary Incident Response Team led by Director of Security with 20 years IT experience
- Audit Committee oversees enterprise risks, including privacy and cybersecurity, with bi-annual reviews involving legal and executive leadership
- Board of Directors receives periodic updates on cybersecurity risks and risk management from executive leadership
- Data Privacy and Security Committee meets quarterly to discuss cybersecurity risk management and reports to Audit Committee
Management Discussion & Analysis
- No profitability or margin percentages reported
- No cash flow, buybacks, dividends, or capex figures stated
- Forward-looking risks and uncertainties highlighted, no specific guidance or outlook provided
AI summary of the BBIO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New regulatory risk: CMS finalized GLOBE on October 2, 2026, requiring internationally benchmarked Medicare Part B rebates beginning January 1, 2027
- Most material update: FDA scrutiny of promotional practices, including an untitled letter concerning Attruby’s DTC broadcast advertisement
- Compliance exposure: Medicaid, 340B and VA pricing errors could trigger refunds, civil penalties, or program termination
- Commercial risk: Attruby faces competition as it is not the first ATTR-CM treatment on the market
- Supply risk: Attruby and Beyonttra rely on one primary drug-product supplier, despite a secondary supplier agreement
Management Discussion & Analysis
- Revenue $353.2M, up $232.5M YoY, driven by Attruby product revenue $253.3M vs $108.1M
- Operating margin negative 3.3% vs negative 120.3% YoY, based on operating loss $11.6M vs $145.2M
- Best line: Attruby revenue up $145.3M; worst line: license and services revenue up $71.0M, boosted by a $75.0M Bayer milestone
- Cash, equivalents and securities $1.5B vs $587.5M; operating cash outflow $312.6M for nine months
- Near-term losses expected for several years; liquidity projected for at least 12 months, with headwinds from commercialization, inflation and supply chain issues
AI summary of the BBIO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 revenue $353.2M, including Attruby product revenue $253.2M, up $145.2M year over year
- Attruby adoption accelerating in treatment-naïve patients, strengthening commercial momentum in ATTR-CM
Item 2.02: Results of Operations and Financial Condition
- Third-quarter results for period ended September 30, 2026, covering financial performance and recent business updates
- Exhibit 99.1 contains the full earnings release, the primary source for detailed results and guidance
Item 8.01: Other Events
- FDA accepted BridgeBio’s NDA for oral infigratinib in children with achondroplasia
- Priority review accelerates FDA evaluation and may shorten the path to potential approval
Item EX-99.1: Item EX-99.1
- FDA accepted oral infigratinib NDA with Priority Review, setting a February 4, 2027 PDUFA target date
- Potential first approved oral achondroplasia therapy, supporting BridgeBio’s planned U.S. launch upon approval
Item EX-99.1: Item EX-99.1
- Voluntary U.S. agreement expands Medicaid access to Attruby through the GENEROUS Model
- Attruby remains available through Medicare Part D without future pricing mandates
Item 8.01: Other Events
- Agreement with U.S. government targets affordability and access for BridgeBio’s future medicines
- Pricing commitment expected to exclude medicines approved exclusively for orphan indications
AI summaries of BBIO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BBIO
Don't miss the next BBIO filing
- Alerts as it files. A push when BBIO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BBIO, by share count.
- Ask anything. An AI agent that reads every BBIO filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kumar Neil | Sell | Nov 19, 2026 | 8,500 | $78.35 |
| Kumar Neil | Sell | Nov 19, 2026 | 1,500 | $79.29 |
| Kumar Neil | Sell | Nov 18, 2026 | 30,490 | $77.83 |
| Kumar Neil | Sell | Nov 18, 2026 | 8,723 | $77.83 |
| Kumar Neil | Sell | Nov 18, 2026 | 4,490 | $76.99 |
| Kumar Neil | Sell | Nov 18, 2026 | 1,277 | $76.99 |
| Kumar Neil | F | Nov 16, 2026 | 36,236 | $77.36 |
| Kumar Neil | M | Nov 16, 2026 | 6,519 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $221.9M | $502.1M |
| Operating Income | -$607.4M | -$593.0M | -$523.4M |
| Net Income | -$643.2M | -$535.8M | -$724.9M |
| Op. Margin | - | -267.2% | -104.2% |
| Net Margin | - | -241.4% | -144.4% |
| Balance Sheet | |||
| Total Assets | $546.4M | $919.3M | $936.0M |
| Equity | - | -$1.5B | -$2.1B |
| ROE | - | 36.5% | 34.7% |
| Per Share | |||
| EPS | $-3.95 | $-2.88 | $-3.78 |
| Cash Flow | |||
| Operating CF | - | -$520.7M | -$445.9M |
| CapEx | - | $933K | $1.1M |
Source: XBRL data in BridgeBio Pharma, Inc. (BBIO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BBIO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 35 | $4.97B |
| Q2 2026 | 38 | $5.74B |
| Q1 2026 | 37 | $6.17B |
| Q4 2025 | 29 | $6.00B |
| Q3 2025 | 31 | $4.07B |
| Q2 2025 | 30 | $3.43B |
| Q1 2025 | 26 | $2.13B |
| Q4 2024 | 21 | $1.51B |
- JPMorgan Chase & Co+1.60M (+67%)
- Franklin Resources+1.12M (+52%)
- AQR Capital Management+817.3K (+490%)
- Citigroup+812.4K (+94%)
- Invesco Ltd+616.0K (+17%)
- Citadel Advisors LLC−2.03M (-54%)
- D.E. Shaw & Co−1.41M (-39%)
- Two Sigma Investments−1.06M (-22%)
- Goldman Sachs Group−435.3K (-24%)
- Morgan Stanley−420.0K (-25%)
- FMR LLC (Fidelity)−2.06M
- Blackstone Group−5.0K
- StoneX Group Inc.−3.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 247 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BBIO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 4 | Sep 21, 2026 | - | - | - |
| 8-K | Aug 31, 2026 | - | Analysis | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Aug 3, 2026 | - | - | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jul 13, 2026 | - | - | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BBIO SEC filings: frequently asked questions
Are BBIO insiders buying or selling?
In the last 90 days, BridgeBio Pharma, Inc. (BBIO) officers, directors and 10% owners reported no open-market purchases and 9 open-market sales worth $5.1 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BBIO stock?
As of September 30, 2026, the largest BridgeBio Pharma, Inc. (BBIO) holders among the 13F filers tracked by SignalX were BlackRock ($683.6 million), Viking Global Investors ($644.3 million), Vanguard Capital Management LLC ($520.7 million), Vanguard Portfolio Management LLC ($492.5 million), State Street Corp ($327.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BBIO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), BridgeBio Pharma, Inc. (BBIO) reported revenue of $502.1 million (up 126.3% from FY2024) and a net loss of $724.9 million. Diluted EPS was -$3.78. The figures come from the XBRL data in the 10-K.
What are the main risks in BBIO's latest 10-K?
In the 10-K filed February 24, 2026, BridgeBio Pharma, Inc. (BBIO) flagged: Cybersecurity risk managed by multidisciplinary Incident Response Team led by Director of Security with 20 years IT experience. Audit Committee oversees enterprise risks, including privacy and cybersecurity, with bi-annual reviews involving legal and executive leadership. (AI summary of the Risk Factors section.)
What did BBIO report in its latest 8-K?
BridgeBio Pharma, Inc. (BBIO) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $353.2M, including Attruby product revenue $253.2M, up $145.2M year over year.
What are the latest BBIO SEC filings?
BridgeBio Pharma, Inc. (BBIO) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 20, 2026.
What is BBIO's SEC CIK number?
BridgeBio Pharma, Inc. (BBIO)'s SEC Central Index Key (CIK) is 1743881. EDGAR lists every BBIO filing under that number.
Ask anything about BBIO
The research agent reads BBIO's filings, financials, insider trades and 13F holders, then answers with sources.